Drug Profile
SC 004 - AbbVie
Alternative Names: SC-004 - AbbVieLatest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator AbbVie
- Class Antibodies; Antineoplastics; Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for phase-I development in Endometrial-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 28 Jul 2020 No recent reports of development identified for phase-I development in Endometrial-cancer(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV)
- 28 Jul 2020 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)